Hummingbird Bioscience is an innovative biotherapeutics company focused on the discovery and development of new breakthrough therapies.
Hummingbird Bioscience is on a mission to unravel the complexities of human disease and revolutionize treatment outcomes.
Hummingbird Bioscience was founded in 2014 by Piers Ingram and Jerome Boyd-Kirkup. The company is headquartered in Singapore, Singapore, with offices in Houston, Texas and San Francisco, California.
Hummingbird develops precision therapeutic antibodies to clinical proof-of-concept for patients with the highest unmet need.
Hummingbird applies computationally guided platforms to discover and engineer breakthrough biotherapeutics by using systems biology to develop unparalleled insights into disease biology.
Hummingbird Bioscience has a pipeline of first or best-in-class drug candidates. Within its pipeline, HMBD-001 (anti-HER3 antibody) and HMBD-002 (anti-VISTA antibody) are anticipated to start clinical trials in 2020.
Hummingbird Bioscience is backed by SK Holdings, Heritas Capital, Mirae Asset Venture Investment, GNTech Venture Capital, SEEDS Capital, Enterprise Singapore and others. The company raised $25M in a Series B round on May 10, 2020. This brings Hummingbird Bioscience's total funding to over $60M to date.